nach oben

Reactions Weekly

Erschienen in:

01.08.2019 | Case report

Cisplatin/etoposide

Myelosuppression: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Excerpt

In a study of 18 patients diagnosed with small cell lung cancer (SCLC) between June 2016 and June 2018, a patient [age and sex not stated] was described, who developed grade IV myelosuppression during treatment with etoposide 100 mg/m² from days 1−3 and cisplatin 75 mg/m² on day 1 for SCLC. Subsequently, myelosuppression improved after symptomatic treatment [routes and duration of treatments to reaction onset not stated]. …

Wan G, et al. Value of dual-input perfusion of 320 row CT on the efficacy evaluation of small cell lung cancer. [Chinese]. Cancer Research and Clinic 31: 162-166, No. 3, Mar 2019. Available from: URL: http://doi.org/10.3760/cma.j.issn.1006-9801.2019.03.005 [Chinese; summarised from a translation] -China

Titel: Cisplatin/etoposide
Myelosuppression: case report
Publikationsdatum: 01.08.2019
Verlag: Springer International Publishing
Erschienen in: Reactions Weekly / Ausgabe 1/2019
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-019-65866-5

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Cisplatin/etoposide

Myelosuppression: case report

Excerpt

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2019

Apixaban/Dabigatran-etexilate

Didanosine

Immunosuppressants

Ipilimumab/nivolumab

Asparaginase

Morphine/sevoflurane